Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy

Randall, Michael P.; Spinner, Michael A.

doi:10.3390/cancers15184509

Cited by 6 publications

(2 citation statements)

References 156 publications

(189 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients received four induction cycles with nivolumab plus brentuximab vedotin; those without complete metabolic response (Deauville score > 3) received brentuximab vedotin plus bendamustine intensification. Complete metabolic response rate was observed in 59% of individuals after induction with nivolumab plus brentuximab vedotin [ 14 , 15 , 16 ]. Sun et al performed a systematic review and meta-analysis of 20 prospective studies assessing the effectiveness and safety of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma

Marjańska,

Pawińska-Wąsikowska,

Wieczorek

et al. 2024

Cancers

View full text Add to dashboard Cite

Background/aim: The role of immune checkpoint inhibitors (ICIs; anti-PD1) in the treatment of childhood cancers is still evolving. The aim of this nationwide retrospective study was to assess the safety and effectiveness of ICIs used in a group of 42 patients, with a median age of 13.6 years, with various types of advanced malignancies treated in pediatric oncology centers in Poland between 2015 and 2023. Results: The indications for treatment with anti-PD1 were as follows: Hodgkin lymphoma (11); malignant skin melanoma (9); neuroblastoma (8); and other malignancies (14). At the end of follow-up, complete remission (CR) was observed in 37.7% (15/42) of children and disease stabilization in 9.5% (4/42), with a mean survival 3.6 (95% CI = 2.6–4.6) years. The best survival (OS = 1.0) was observed in the group of patients with Hodgkin lymphoma. For malignant melanoma of the skin, neuroblastoma, and other rare malignancies, the estimated 3-year OS values were, respectively, 0.78, 0.33, and 0.25 (p = 0.002). The best progression-free survival value (0.78) was observed in the group with malignant melanoma. Significantly better effects of immunotherapy were confirmed in patients ≥ 14 years of age and good overall performance ECOG status. Severe adverse events were observed in 30.9% (13/42) patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma

Marjańska,

Pawińska-Wąsikowska,

Wieczorek

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Reduction of toxicities, optimization of CAR-design and combination regimens with other therapeutic agents are further areas of promising research ( 313 ). The integration of technologies like mass cytometry, single-cell RNA sequencing, and monitoring of circulating tumor DNA promise more detailed insights into the pathophysiology of HL and potential new molecular targets ( 314 ).…”

Section: Discussionmentioning

confidence: 99%

Broadening the horizon: potential applications of CAR-T cells beyond current indications

Karsten,

Matrisch,

Cichutek

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Engineering immune cells to treat hematological malignancies has been a major focus of research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several diseases can now be treated in highly therapy-refractory or relapsed conditions. Currently, a number of CD19- or BCMA-specific CAR-T-cell therapies are approved for acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma (MM), and follicular lymphoma (FL). The implementation of these therapies has significantly improved patient outcome and survival even in cases with previously very poor prognosis. In this comprehensive review, we present the current state of research, recent innovations, and the applications of CAR-T-cell therapy in a selected group of hematologic malignancies. We focus on B- and T-cell malignancies, including the entities of cutaneous and peripheral T-cell lymphoma (T-ALL, PTCL, CTCL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), classical Hodgkin-Lymphoma (HL), Burkitt-Lymphoma (BL), hairy cell leukemia (HCL), and Waldenström’s macroglobulinemia (WM). While these diseases are highly heterogenous, we highlight several similarly used approaches (combination with established therapeutics, target depletion on healthy cells), targets used in multiple diseases (CD30, CD38, TRBC1/2), and unique features that require individualized approaches. Furthermore, we focus on current limitations of CAR-T-cell therapy in individual diseases and entities such as immunocompromising tumor microenvironment (TME), risk of on-target-off-tumor effects, and differences in the occurrence of adverse events. Finally, we present an outlook into novel innovations in CAR-T-cell engineering like the use of artificial intelligence and the future role of CAR-T cells in therapy regimens in everyday clinical practice.

show abstract

Pitfalls in the Cytological Diagnosis of Nodal Hodgkin Lymphoma

Handa,

Mohamedali,

Punia

et al. 2024

Diagnostic Cytopathology

View full text Add to dashboard Cite

BackgroundHodgkin lymphoma (HL) is a hematopoietic neoplasm characterized by malignant Reed–Sternberg (RS) cells in an inflammatory background. Although the cytological features of HL are well elucidated in literature, yet many postulated factors cause its misdiagnosis. This study aims to assess the diagnostic reliability of fine needle aspiration cytology (FNAC) in HL and evaluate the factors contributing to a false‐negative and false‐positive diagnosis, taking histopathology as the gold standard.MethodsThis was a retrospective study in which 47 cases of HL diagnosed on histopathology were compared with their prior cytological diagnosis.ResultsThe patient's age ranged from 3 to 80 years (median: 36 years) with a M:F ratio of 2.9:1. Lymph node aspirations were performed from multiple anatomical sites, out of which the cervical was the most common (57.8%). FNAC was inconclusive in two cases due to unsatisfactory smears. The false‐negative diagnosis of reactive lymphadenitis was given in four cases, and false‐positive in four cases, which included three cases of non‐HL, and one case of malignant small round blue cell tumor. The overall diagnostic accuracy of FNAC in the diagnosis of HL was 82.2%.ConclusionsThe cytological diagnosis of HL can be challenging when classic RS cells are absent. Contributing factors for a false‐negative diagnosis include obscuring reactive inflammatory cells, fibrosis of the involved lymph nodes, partial involvement of the lymph node, and misinterpretation. A thorough clinical examination with evaluation of FNAC smears from multiple areas, and ancillary tests help improve the diagnostic accuracy of cytological diagnosis.

show abstract

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy

Cited by 6 publications

References 156 publications

Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma

Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma

Broadening the horizon: potential applications of CAR-T cells beyond current indications

Pitfalls in the Cytological Diagnosis of Nodal Hodgkin Lymphoma

Contact Info

Product

Resources

About